Concepedia

Darren C. Phillips

DC

32

Publications

6.2K

Citations

26

H-Index

2002

Active since

Affiliations

AbbVie (United States)(Current)

Aston University

St. Jude Children's Research Hospital

The University of Melbourne

Walter and Eliza Hall Institute of Medical Research

Darren C. Phillips is an author at AbbVie (United States) specializing in medicine, cell biology, and cell death.

ORCID

Top concepts

Publications per year

2002–2024

32

Publications

32

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Andrew J. Souers, Erwin R. Boghaert, Scott Ackler et al. · Nature Medicine · 2013 · 2.9K citations

, , +11

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Darren C. Phillips, Michael J. Mitten, Erwin R. Boghaert et al. · Science Translational Medicine · 2015 · 530 citations · Full text

, , +20

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

H Zhang, J Chen, Sajid Khan Tahir et al. · Cell Death and Disease · 2015 · 427 citations · Full text

Discovery of a Potent and Selective BCL-X <sub>L</sub> Inhibitor with <i>in Vivo</i> Activity

Zhi‐Fu Tao, Lisa Hasvold, Le Wang et al. · ACS Medicinal Chemistry Letters · 2014 · 328 citations · Full text

5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis

Sha Jin, Dan Cojocari, Julie J. Purkal et al. · Clinical Cancer Research · 2020 · 187 citations

Rows per page

1–5 of 32